Peptide Transport and Delivery into the Central Nervous System:
Hypo- or hypersecretion, alteration in storage, release, catabolism, and post-translational processing of neuropeptides are associated with the etiology of many diseases affecting the central nervous system (CNS). Various peptides native to the brain and the spinal cord, as well as various synthetic...
Gespeichert in:
Weitere Verfasser: | , |
---|---|
Format: | Elektronisch E-Book |
Sprache: | English |
Veröffentlicht: |
Basel
Birkhäuser Basel
2003
|
Schriftenreihe: | Progress in Drug Research
61 |
Schlagworte: | |
Online-Zugang: | DE-355 Volltext |
Zusammenfassung: | Hypo- or hypersecretion, alteration in storage, release, catabolism, and post-translational processing of neuropeptides are associated with the etiology of many diseases affecting the central nervous system (CNS). Various peptides native to the brain and the spinal cord, as well as various synthetic peptides, peptide analogues and peptidomimetics developed as their agonists or antagonists could be useful in the treatment of these CNS maladies. However, peptides face a formidable obstacle in reaching the intended site of action due to the existence of the blood-brain barrier (BBB), a vital element in the regulation of the internal environment of the brain and the spinal cord. After reviews on the role and neuropharmaceutical potential of peptides, properties of the BBB in the context of peptide transport in the CNS and potential transport mechanisms to cross the BBB, this volume discusses the development, present state-of-the-art and future trends of various strategies to overcome this major obstacle to peptide pharmacotherapy involving the CNS. Chapters are devoted to cover invasive approaches that circumvent the BBB by direct administration into the brain or the spinal cord and by transiently opening the tight junctions of or permeabilizing the endothelial cells separating the systemic circulation from the interstitial fluid of the CNS. Subsequently, physiologically based strategies that utilize biological carriers to gain access to the CNS are discussed in detail, followed by methods encompassing prodrug and chemical delivery/targeting strategies, which aim at altering the properties of the peptide to enhance BBB transport, and drug delivery strategies based on peptide vectors. Finally, a comparative evaluation on the present status and perspectives of the techniques is presented |
Beschreibung: | 1 Online-Ressource (VIII, 245 p) |
ISBN: | 9783034880497 |
DOI: | 10.1007/978-3-0348-8049-7 |
Internformat
MARC
LEADER | 00000nmm a2200000zcb4500 | ||
---|---|---|---|
001 | BV046149257 | ||
003 | DE-604 | ||
007 | cr|uuu---uuuuu | ||
008 | 190906s2003 |||| o||u| ||||||eng d | ||
020 | |a 9783034880497 |9 978-3-0348-8049-7 | ||
024 | 7 | |a 10.1007/978-3-0348-8049-7 |2 doi | |
035 | |a (ZDB-2-SBL)978-3-0348-8049-7 | ||
035 | |a (OCoLC)1119116385 | ||
035 | |a (DE-599)BVBBV046149257 | ||
040 | |a DE-604 |b ger |e aacr | ||
041 | 0 | |a eng | |
049 | |a DE-355 | ||
082 | 0 | |a 615 |2 23 | |
245 | 1 | 0 | |a Peptide Transport and Delivery into the Central Nervous System |c edited by Laszlo Prokai, Katalin Prokai-Tatrai |
264 | 1 | |a Basel |b Birkhäuser Basel |c 2003 | |
300 | |a 1 Online-Ressource (VIII, 245 p) | ||
336 | |b txt |2 rdacontent | ||
337 | |b c |2 rdamedia | ||
338 | |b cr |2 rdacarrier | ||
490 | 0 | |a Progress in Drug Research |v 61 | |
520 | |a Hypo- or hypersecretion, alteration in storage, release, catabolism, and post-translational processing of neuropeptides are associated with the etiology of many diseases affecting the central nervous system (CNS). Various peptides native to the brain and the spinal cord, as well as various synthetic peptides, peptide analogues and peptidomimetics developed as their agonists or antagonists could be useful in the treatment of these CNS maladies. However, peptides face a formidable obstacle in reaching the intended site of action due to the existence of the blood-brain barrier (BBB), a vital element in the regulation of the internal environment of the brain and the spinal cord. After reviews on the role and neuropharmaceutical potential of peptides, properties of the BBB in the context of peptide transport in the CNS and potential transport mechanisms to cross the BBB, this volume discusses the development, present state-of-the-art and future trends of various strategies to overcome this major obstacle to peptide pharmacotherapy involving the CNS. Chapters are devoted to cover invasive approaches that circumvent the BBB by direct administration into the brain or the spinal cord and by transiently opening the tight junctions of or permeabilizing the endothelial cells separating the systemic circulation from the interstitial fluid of the CNS. Subsequently, physiologically based strategies that utilize biological carriers to gain access to the CNS are discussed in detail, followed by methods encompassing prodrug and chemical delivery/targeting strategies, which aim at altering the properties of the peptide to enhance BBB transport, and drug delivery strategies based on peptide vectors. Finally, a comparative evaluation on the present status and perspectives of the techniques is presented | ||
650 | 4 | |a Pharmacology/Toxicology | |
650 | 4 | |a Medicine/Public Health, general | |
650 | 4 | |a Life Sciences, general | |
650 | 4 | |a Toxicology | |
650 | 4 | |a Medicine | |
650 | 4 | |a Life sciences | |
650 | 0 | 7 | |a Neuropeptide |0 (DE-588)4041895-9 |2 gnd |9 rswk-swf |
650 | 0 | 7 | |a Krankheit |0 (DE-588)4032844-2 |2 gnd |9 rswk-swf |
650 | 0 | 7 | |a Therapie |0 (DE-588)4059798-2 |2 gnd |9 rswk-swf |
650 | 0 | 7 | |a Zentralnervensystem |0 (DE-588)4067637-7 |2 gnd |9 rswk-swf |
655 | 7 | |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
689 | 0 | 0 | |a Zentralnervensystem |0 (DE-588)4067637-7 |D s |
689 | 0 | 1 | |a Krankheit |0 (DE-588)4032844-2 |D s |
689 | 0 | 2 | |a Neuropeptide |0 (DE-588)4041895-9 |D s |
689 | 0 | 3 | |a Therapie |0 (DE-588)4059798-2 |D s |
689 | 0 | |5 DE-604 | |
700 | 1 | |a Prokai, Laszlo |4 edt | |
700 | 1 | |a Prokai-Tatrai, Katalin |4 edt | |
776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9783764367169 |
776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9783034894203 |
776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9783034880503 |
856 | 4 | 0 | |u https://doi.org/10.1007/978-3-0348-8049-7 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
912 | |a ZDB-2-SBL | ||
940 | 1 | |q ZDB-2-SBL_2000/2004 | |
943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-031529434 | |
966 | e | |u https://doi.org/10.1007/978-3-0348-8049-7 |l DE-355 |p ZDB-2-SBL |q ZDB-2-SBL_2000/2004 |x Verlag |3 Volltext |
Datensatz im Suchindex
_version_ | 1807322312174731264 |
---|---|
adam_text | |
any_adam_object | |
author2 | Prokai, Laszlo Prokai-Tatrai, Katalin |
author2_role | edt edt |
author2_variant | l p lp k p t kpt |
author_facet | Prokai, Laszlo Prokai-Tatrai, Katalin |
building | Verbundindex |
bvnumber | BV046149257 |
collection | ZDB-2-SBL |
ctrlnum | (ZDB-2-SBL)978-3-0348-8049-7 (OCoLC)1119116385 (DE-599)BVBBV046149257 |
dewey-full | 615 |
dewey-hundreds | 600 - Technology (Applied sciences) |
dewey-ones | 615 - Pharmacology and therapeutics |
dewey-raw | 615 |
dewey-search | 615 |
dewey-sort | 3615 |
dewey-tens | 610 - Medicine and health |
discipline | Medizin |
doi_str_mv | 10.1007/978-3-0348-8049-7 |
format | Electronic eBook |
fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>00000nmm a2200000zcb4500</leader><controlfield tag="001">BV046149257</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">190906s2003 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783034880497</subfield><subfield code="9">978-3-0348-8049-7</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/978-3-0348-8049-7</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-2-SBL)978-3-0348-8049-7</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1119116385</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV046149257</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615</subfield><subfield code="2">23</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Peptide Transport and Delivery into the Central Nervous System</subfield><subfield code="c">edited by Laszlo Prokai, Katalin Prokai-Tatrai</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Basel</subfield><subfield code="b">Birkhäuser Basel</subfield><subfield code="c">2003</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (VIII, 245 p)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Progress in Drug Research</subfield><subfield code="v">61</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Hypo- or hypersecretion, alteration in storage, release, catabolism, and post-translational processing of neuropeptides are associated with the etiology of many diseases affecting the central nervous system (CNS). Various peptides native to the brain and the spinal cord, as well as various synthetic peptides, peptide analogues and peptidomimetics developed as their agonists or antagonists could be useful in the treatment of these CNS maladies. However, peptides face a formidable obstacle in reaching the intended site of action due to the existence of the blood-brain barrier (BBB), a vital element in the regulation of the internal environment of the brain and the spinal cord. After reviews on the role and neuropharmaceutical potential of peptides, properties of the BBB in the context of peptide transport in the CNS and potential transport mechanisms to cross the BBB, this volume discusses the development, present state-of-the-art and future trends of various strategies to overcome this major obstacle to peptide pharmacotherapy involving the CNS. Chapters are devoted to cover invasive approaches that circumvent the BBB by direct administration into the brain or the spinal cord and by transiently opening the tight junctions of or permeabilizing the endothelial cells separating the systemic circulation from the interstitial fluid of the CNS. Subsequently, physiologically based strategies that utilize biological carriers to gain access to the CNS are discussed in detail, followed by methods encompassing prodrug and chemical delivery/targeting strategies, which aim at altering the properties of the peptide to enhance BBB transport, and drug delivery strategies based on peptide vectors. Finally, a comparative evaluation on the present status and perspectives of the techniques is presented</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmacology/Toxicology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Medicine/Public Health, general</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Life Sciences, general</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Toxicology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Medicine</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Life sciences</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Neuropeptide</subfield><subfield code="0">(DE-588)4041895-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Krankheit</subfield><subfield code="0">(DE-588)4032844-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Therapie</subfield><subfield code="0">(DE-588)4059798-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Zentralnervensystem</subfield><subfield code="0">(DE-588)4067637-7</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Zentralnervensystem</subfield><subfield code="0">(DE-588)4067637-7</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Krankheit</subfield><subfield code="0">(DE-588)4032844-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Neuropeptide</subfield><subfield code="0">(DE-588)4041895-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="3"><subfield code="a">Therapie</subfield><subfield code="0">(DE-588)4059798-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Prokai, Laszlo</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Prokai-Tatrai, Katalin</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9783764367169</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9783034894203</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9783034880503</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1007/978-3-0348-8049-7</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-SBL</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">ZDB-2-SBL_2000/2004</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-031529434</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1007/978-3-0348-8049-7</subfield><subfield code="l">DE-355</subfield><subfield code="p">ZDB-2-SBL</subfield><subfield code="q">ZDB-2-SBL_2000/2004</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
genre | (DE-588)4143413-4 Aufsatzsammlung gnd-content |
genre_facet | Aufsatzsammlung |
id | DE-604.BV046149257 |
illustrated | Not Illustrated |
indexdate | 2024-08-14T00:54:30Z |
institution | BVB |
isbn | 9783034880497 |
language | English |
oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-031529434 |
oclc_num | 1119116385 |
open_access_boolean | |
owner | DE-355 DE-BY-UBR |
owner_facet | DE-355 DE-BY-UBR |
physical | 1 Online-Ressource (VIII, 245 p) |
psigel | ZDB-2-SBL ZDB-2-SBL_2000/2004 ZDB-2-SBL ZDB-2-SBL_2000/2004 |
publishDate | 2003 |
publishDateSearch | 2003 |
publishDateSort | 2003 |
publisher | Birkhäuser Basel |
record_format | marc |
series2 | Progress in Drug Research |
spelling | Peptide Transport and Delivery into the Central Nervous System edited by Laszlo Prokai, Katalin Prokai-Tatrai Basel Birkhäuser Basel 2003 1 Online-Ressource (VIII, 245 p) txt rdacontent c rdamedia cr rdacarrier Progress in Drug Research 61 Hypo- or hypersecretion, alteration in storage, release, catabolism, and post-translational processing of neuropeptides are associated with the etiology of many diseases affecting the central nervous system (CNS). Various peptides native to the brain and the spinal cord, as well as various synthetic peptides, peptide analogues and peptidomimetics developed as their agonists or antagonists could be useful in the treatment of these CNS maladies. However, peptides face a formidable obstacle in reaching the intended site of action due to the existence of the blood-brain barrier (BBB), a vital element in the regulation of the internal environment of the brain and the spinal cord. After reviews on the role and neuropharmaceutical potential of peptides, properties of the BBB in the context of peptide transport in the CNS and potential transport mechanisms to cross the BBB, this volume discusses the development, present state-of-the-art and future trends of various strategies to overcome this major obstacle to peptide pharmacotherapy involving the CNS. Chapters are devoted to cover invasive approaches that circumvent the BBB by direct administration into the brain or the spinal cord and by transiently opening the tight junctions of or permeabilizing the endothelial cells separating the systemic circulation from the interstitial fluid of the CNS. Subsequently, physiologically based strategies that utilize biological carriers to gain access to the CNS are discussed in detail, followed by methods encompassing prodrug and chemical delivery/targeting strategies, which aim at altering the properties of the peptide to enhance BBB transport, and drug delivery strategies based on peptide vectors. Finally, a comparative evaluation on the present status and perspectives of the techniques is presented Pharmacology/Toxicology Medicine/Public Health, general Life Sciences, general Toxicology Medicine Life sciences Neuropeptide (DE-588)4041895-9 gnd rswk-swf Krankheit (DE-588)4032844-2 gnd rswk-swf Therapie (DE-588)4059798-2 gnd rswk-swf Zentralnervensystem (DE-588)4067637-7 gnd rswk-swf (DE-588)4143413-4 Aufsatzsammlung gnd-content Zentralnervensystem (DE-588)4067637-7 s Krankheit (DE-588)4032844-2 s Neuropeptide (DE-588)4041895-9 s Therapie (DE-588)4059798-2 s DE-604 Prokai, Laszlo edt Prokai-Tatrai, Katalin edt Erscheint auch als Druck-Ausgabe 9783764367169 Erscheint auch als Druck-Ausgabe 9783034894203 Erscheint auch als Druck-Ausgabe 9783034880503 https://doi.org/10.1007/978-3-0348-8049-7 Verlag URL des Erstveröffentlichers Volltext |
spellingShingle | Peptide Transport and Delivery into the Central Nervous System Pharmacology/Toxicology Medicine/Public Health, general Life Sciences, general Toxicology Medicine Life sciences Neuropeptide (DE-588)4041895-9 gnd Krankheit (DE-588)4032844-2 gnd Therapie (DE-588)4059798-2 gnd Zentralnervensystem (DE-588)4067637-7 gnd |
subject_GND | (DE-588)4041895-9 (DE-588)4032844-2 (DE-588)4059798-2 (DE-588)4067637-7 (DE-588)4143413-4 |
title | Peptide Transport and Delivery into the Central Nervous System |
title_auth | Peptide Transport and Delivery into the Central Nervous System |
title_exact_search | Peptide Transport and Delivery into the Central Nervous System |
title_full | Peptide Transport and Delivery into the Central Nervous System edited by Laszlo Prokai, Katalin Prokai-Tatrai |
title_fullStr | Peptide Transport and Delivery into the Central Nervous System edited by Laszlo Prokai, Katalin Prokai-Tatrai |
title_full_unstemmed | Peptide Transport and Delivery into the Central Nervous System edited by Laszlo Prokai, Katalin Prokai-Tatrai |
title_short | Peptide Transport and Delivery into the Central Nervous System |
title_sort | peptide transport and delivery into the central nervous system |
topic | Pharmacology/Toxicology Medicine/Public Health, general Life Sciences, general Toxicology Medicine Life sciences Neuropeptide (DE-588)4041895-9 gnd Krankheit (DE-588)4032844-2 gnd Therapie (DE-588)4059798-2 gnd Zentralnervensystem (DE-588)4067637-7 gnd |
topic_facet | Pharmacology/Toxicology Medicine/Public Health, general Life Sciences, general Toxicology Medicine Life sciences Neuropeptide Krankheit Therapie Zentralnervensystem Aufsatzsammlung |
url | https://doi.org/10.1007/978-3-0348-8049-7 |
work_keys_str_mv | AT prokailaszlo peptidetransportanddeliveryintothecentralnervoussystem AT prokaitatraikatalin peptidetransportanddeliveryintothecentralnervoussystem |